Drug Approval | March 22, 2023
Zydus granted Orphan Drug Designation by USFDA for ZYIL1
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
The Indian government will float a global tender in April 2023 to procure HPV vaccines.
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
Various healthcare companies are already implementing high-tech solutions into existing healthcare systems.
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
ELL will be the preferred source of supply for some the key Raw Materials to VPPL at "Arm's Length" transaction.
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
“One Earth, One Health” vision can become a reality only with active global collaboration where countries don’t think of only themselves, but of collective global outcomes
A funding to expand operations and provide better patient care
Proposed combination enhances Pfizer’s position as a leading company in oncology
Subscribe To Our Newsletter & Stay Updated
